StemCell Therapy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at http://www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

As with many websites, JD Supra's website (located at http://www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

We use cookies and other tracking technologies to:

There are different types of cookies and other technologies used our Website, notably:

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

View original post here:
USDOL Issues Opinion Letter On Inclusion of Longevity Bonus In The Regular Rate - JD Supra

Recessions save lives. This statistical truth has been a thorn in the side of capitalism and neoliberalism, and a befuddling conundrum for economists and sociologists. This conveniently ignored inconvenient truth has been the subject of much investigation, but none of the umpteen interdisciplinary studies probing the enigma have yielded substantial or convincing insight.

Perhaps the ideological perturbation posed to the Western world by this fact has held back its evaluation economic inequality. However, the advocates of economic booms have little to worry about unless theyre plutocrats. In the long term, the positive relationship between economic growth and longevity is well established.

A lot of reputable research literature exists depicting a just-as-consistent and certain association of periods of recessions with increased longevity. However, a similar volume of counter-indicative literature exists that criticizes the formers methodologies, proposes a lagging causality (delayed materialization of effects) of macroeconomic cycles and phases with life expectancies.

Even articles published in the worlds premier scientific journal Nature are divided on the issue. However, what we can be sure of is that every major recession period has been accompanied by a conspicuous decline in mortality rates.

The fact that notable recession events have gone hand-in-hand with conspicuously lower mortality rates has been known ever since William Ogburn and Dorothy Thomas, sociologists at New Yorks Columbia University, analyzed 50 years worth of US economic and mortality data. The duo, being seasoned and keen researchers, were wary of mistaking mere correlation for causality a classic attributive fallacy.

They inspected two probable pitfalls a possible lag between economic downturn and rise in deaths, that is, whether the adverse health effects of scarcity took effect after a while, and if documentation of deaths was more discreet and meticulous during booms. Their further scrutiny categorically ruled both of these out. Eminent social epidemiologist Edgar Sydenstricker wrote to the US Public Health Service in 1933, at the beginning of the Great Depression. Other major recession events follow suit.

According to statistics from the International Labor Organization, around 2.3 million people succumb to work-related accidents or diseases every year. ILO data also show that 340 million occupational incidents transpire annually, while 140 million victims suffer from occupation-related ailments.

Injuries claimed almost 5 million lives in 2016, about 30% of which were in road/traffic-related accidents, according to statistics presented as part of the Global Health Estimates by the World Health Organization.

In the same data, once can observe that the respiratory ailments chronic obstructive pulmonary disease, lower respiratory infection, and cancer of the trachea, bronchus or lungs are three of the leading causes of death, consistently featuring in the top 10 places, with the former occupying two of the top five spots, year after year. Many of these cases are caused or contributed to by two man-made factors: pollution and chronic smoking. Smoking results in about 8.2 million deaths annually.

On the issue of air-pollution-related mortality, the WHO says, The combined effects of ambient (outdoor) and householdair pollutioncause about 7 million prematuredeaths every year, largely as a result of increasedmortalityfrom stroke, heart disease, chronic obstructive pulmonary disease, lung cancer and acute respiratory infections. The latest research puts it at 8 million.

Pollution and smoking can aggravate existing ailments and weaken the natural recuperative ability and tenacity of respiratory system exposing them to greater jeopardies and increased risks of complications posed by other respiratory ailments. Recent research published in Cardiovascular Research found that air pollution reduces average human life expectancy by three years (for comparison, smoking takes off 2.2 years) and put the annual toll for 2015 at 8.8 million. Water pollution caused 1.8 million deaths in the same year.

During the current Covid-19 pandemic, strict lockdowns are averting workplace accidents, preventing narcotic consumption, reducing vehicular and industrial pollution, and precluding transport-related fatalities. These are the same factors that contribute to a lowering of mortality rates during recessions.

Moreover, less work during recessions also very often translates to more sleep, better diet (carefully home-cooked, balanced and nutritious), less work-related stress, and more opportunity for exercise, leading to amelioration of cardiovascular problems.

Having less money to spare also lowers the consumption of cigarettes and alcohol. Having more time to dedicate to leisurely, creative or recreative pursuits and being with family could also enhance bodily and mental integrity and extend lifespans.

All these factors are currently being amplified during strict nationwide stay-at-home quarantines. Of course, the increased chance of deaths in home accidents such as falling-related injuries, fires, and suffocation should be factored in this. Nevertheless, a protracted and largely unrelenting lockdown is bound to reduce the death rate, given that it eliminates the scopes of multiple leading causes of death.

Economists have foreseen a watershed recession for more than a month now it is now more of a matter of when than if, while some suspect it has already begun. The pandemic has impeded and obstructed supply-chain flows, upset supply-demand equilibria, and incapacitated resource procurement and most forms of production. Social distancing and lockdowns have adversely affected the economy.

Not only does a lockdown exert the same, and more pronounced, effects on longevity as a recession does, but it also leads to recession itself. There is an increase in mortality caused by the disease competing with an increase in longevity caused by industrial, technological and economic incapacitation together these determine the influence of the crisis on life expectancy. There thus exists an optimal point, a sweet spot, for life expectancy that lies at the intersection of primarily three interplaying factors: the extent of the spread of Covid-19, the longevity extension caused by preventive measures, and the longevity extension due to the recession caused thereby.

Of course, the human socioeconomic and political-policy response to it, the lingering of disease-related apprehension, the persistence of precaution, and the permanence of institutional change it ushers in, will determine its specifics. The pandemic is expected to leave a lasting impact not only practically and institutionally but also normatively, ideologically, and psychologically. Hence it would not be an overstatement to say that there might just exist a silver lining amid this morbid semblance, just not a very conspicuous one.

The very existence of this rather obscure bright side depends on how we deal with the epidemic the spread, the mortality rate, and the flattening of the curve the pivotal sweet spot is the fulcrum of the teetering see-saw of demographics, either end of which dips into decrement.

However, the key takeaway is not the greater good or some statistical satisfaction, but a realization of how neglectful we are of threats non-acute in nature those as ubiquitous, sizable and as invisible as the coronavirus, that result from our own actions yet occur so unsystematically and regularly that we stay blissfully ignorant of them. Omnipresent slow killers such as pollution and smoking abound in our world, yet we casually tuck them away in a conveniently remote recess of the mind, informed yet tantalisingly unaware.

Let us not derive a figment of solace and consolation from the salubrious effects of the pandemic but acknowledge the multitude of equally sizaable and pressing hazards that our daily environments abound in, that just happen to be exposed by a competing, more conspicuous and acute threat.

Asia Times Financialis now live. Linking accurate news, insightful analysis and local knowledge with the ATF China Bond 50 Index, the world'sfirst benchmark cross sector Chinese Bond Indices.Read ATFnow.

See the rest here:
Recessions, longevity and the Covid-19 sweet spot - Asia Times

Longevity has played a part in the selections of some of our top 10 Bruins of all-time, but had nothing to do with us choosing Phil Esposito at No. 3 on our list.

He arrived via a trade in 1967 and left the same way in 1975 both deals whoppers for the ages that would have major impacts on the organization. In between he played just 625 games in Black and Gold, the fewest of any modern era skater other than Cam Neely on our list.

But in those eight-plus seasons in Boston, Esposito was the catalyst for the most explosive offensive juggernaut the league had seen to that point and was one of the great characters of arguably the most beloved team in Bostons rich sports history.

In the spring of 1967, the Bs already had a kid in Bobby Orr who would become the greatest defenseman in NHL history and, yes, here in Boston still the greatest player ever but hockey is all about depth. That was provided when the Bs incoming GM Milt Schmidt pulled off a heist, sending forward Pit Martin, defenseman Gilles Marotte and goalie prospect Jack Norris to Chicago for Esposito, Fred Stanfield and Ken Hodge.

Martin would be a mainstay on a very good Blackhawks team, Marotte bounced around the NHL for 10 more years and Norris played 35 more NHL games.

Esposito made the Bruins a cultural phenomenon.

In Chicago, the Blackhawks had the top goal-scorer in the league at that time in Bobby Hull. His centerman Esposito was primarily Hulls playmaker, but that perception would be irrevocably shattered in short order when he arrived in Boston.

Esposito became the first player to break the 100-point mark in a season, posting 49-77-126 totals in 1968-69. As a team, they would finally break through the next year, winning the Stanley Cup for the first time in 29 years.

The next regular season was not only his finest, but the best the league had ever seen from a forward to that point. On March 11, 1971, Esposito, parked in his usual spot in the slot, redirected a Ted Green shot for his 59th goal of the season in a rout of the Los Angeles Kings in the then-Great Western Forum, breaking his former linemate Hulls record of 58.

But he didnt stop there. Esposito potted 76 goals that year, along with 76 assists for 152 points (another record at the time) in 78 games. With linemates Wayne Cashman and Ken Hodge comprising a first line that was impossible to contain, Esposito would hold the records for most goals and points for another decade until Wayne Gretzky came along and rewrote the book. Esposito captured the Art Ross Trophy five times in his eight full seasons with the Bs while Orr won it twice in that time, keeping the award in Boston seven straight seasons (Chicagos Stan Mikita won the award in 1967-68).

While Orr won the Conn Smythe Award as playoff MVP in the Cup seasons of 70 and 72, Esposito was no slouch in the postseason. In the first Cup season he posted 13-14-27 totals in 14 games and in the second Cup run he had 9-15-24 in 15 games. In 71 playoff games with the Bruins, Esposito notched 46-56-102 totals. His 1.437 points per playoff game average is second only to Barry Pedersons 1.529 (20-32-52 in 34 games).

Through all those wild times, Esposito seemed like the life of the party and apparently he was. In a story that epitomized the togetherness of those Big, Bad Bruins, Esposito had once been playfully kidnapped from Mass General Hospital by his teammates. He suffered torn knee ligaments in the second game of a first round series against the Rangers in 1973, thus contributing to an early exit by the Bs. As the story goes, the team decided it could not hold its break-up dinner at the Branding Iron bar without Esposito so dressed in hospital gear, his teammates surreptitiously wheeled him out of the hospital, still in his johnny, and took him straight to the bar.

Good times like that cant last forever, and they didnt.

On Nov. 7, 1975, GM Harry Sinden traded Esposito and defenseman Carol Vadnais to the New York Rangers in exchange for Brad Park the best defenseman in the league not named Orr and classy centerman Jean Ratelle.

The move kept the Bruins among the elite teams in the league and is widely regarded as a big win for the team, but the trade could not quite lift the Bs back to the heights that it achieved with Esposito roaming the slot.

View post:
Phil Esposito owned the slot like no other Bruin - Boston Herald

Life expectancy in the United States is about 78 years, though longevity is not without medical concerns. As many as one in three Americans will develop malignant cells in their lifetime. While the scientific community has significantly increased their understanding of cancer in recent years and applied that knowledge to treatment, prevention research remains a top priority; however, since cancer is a series of diseases, the exact cause is not always known. Genetics plays an important role, yet so does diet and lifestyle.

Dr. Kevin Dalby, professor of chemical biology and medicinal chemistry, is studying the mechanisms of cancer cells and currently working on cancer drug discovery. His research primarily focuses on developing targeted therapeutics, but he does acknowledge that specific behavioral changes can help lower a persons risk for cancer. The Harvard School of Public Health estimates that 75% of American cancer deaths could be prevented if tactics are adopted on a mass scale.

Below, Dr. Kevin Dalby reviews practical behavioral choices that anyone can take up to help prevent cancer, thus reducing the risk of the emotional and the financial burden inflicted by this crippling disease.

Avoid Tobacco

The correlation between tobacco use and cancer is staggering. In the United States, one out of every five deaths is related to tobacco. Moreover, cigarette smoking accounts for 85-90% of lung cancer deaths and 70% of oral and laryngeal cancer deaths.

Tobacco use (smoking or chewing) is a difficult habit to quit. Still, it could help you as well as those around you (secondhand smoke kills) avoid a future collision with the following cancers: lung, mouth, throat, larynx, pancreas, bladder, cervix, and kidney.

Limit Alcohol

Research has yet to pinpoint exactly how alcohol influences your susceptibility for cancer, but excess use does increase the risk for mouth, throat, liver, colon, rectal, and breast cancer. Men should limit their acholic beverages to two a day and women to one. For context, one drink equates to approximately twelve ounces of beer, five ounces of wine, or one and a half ounces of liquor.

Eat A Healthy Diet

40% of cancers are associated with dietary factors: habits, foods, and nutrients all play a role. The American Cancer Society suggests a daily nutritional regimen consisting of whole grains, fish or poultry, and a variety of vegetables and fruits to lower your risk for cancer. Try to limit red and processed meats, eat fewer sweets, and reduce your intake of saturated fats.

Exercise

Regular physical activity helps you maintain a healthy weight, control blood pressure, and may lower the risk for several types of cancer such as colon, prostate, and even breast cancer. Obesity is especially of paramount importance since it has been linked to 20% of all cancer-related deaths.

Adults should strive to exercise moderately for 150 minutes each week. Alternatively, you can aim for 75 minutes of vigorous activity if that suits your lifestyle better.

Sun Protection

Skin cancer is common but also preventable. To reduce your risk, proportionately apply sunscreen, avoid the sun at midday if possible when its rays are most reliable, cover exposed skin and forgo tanning beds and sunlamps, which are just as dangerous as actual sunlight.

Regular Medical Care

Cancer may not be entirely preventable, but if caught early, your chances of survival improve drastically. Schedule regular checkups with your doctor, be transparent, and ask what tests make sense for you. Depending on your sex, age, and medical history, your doctor may recommend screenings for breast, cervical, colon, lung, or prostate cancer.

About Dr. Kevin Dalby:

Dr. Kevin Dalby has been interested in the why of chemical reactions since he was a student at the University of Cambridge, where he graduated with a Doctor of Philosophy degree in Organic Chemistry. This curiosity has led to his interest in the processes of cell signaling, and ultimately to cancer research. Dr. Dalbys research areas include biochemistry, cancer, cell biology, chemical biology, drug discovery & diagnostics, and enzymology.

See the original post here:
Dr. Kevin Dalby on How to Decrease Your Risk of Developing Cancer - Thrive Global

Qualified Longevity Annuity Contracts (QLACs) are future pension strategies that can be used in your Traditional IRA and some select employer sponsored plans. QLACs were first introduced in 2014 by the IRS and the Treasury Department as a way for people to used their qualified (i.e. IRA) assets to plan for future lifetime income guarantees. Social Security payments were never put in place to be the sole source of income in retirement. Our government (i.e. IRS & Treasury Department) want QLACs to be that additional source as part of your overall income floor guarantees.

QLAC funding rules for 2020 is the lesser of 25% of your total IRA assets or $135,000. If you and your spouse/partner have an Traditional IRA, each of you can own a QLAC and add the other spouse/partner for "Joint Life" income.

QLAC income has to be turned on by age 85. You don't have to defer that long for income to start. It can begin as soon as age 72, and the lifetime income stream can be contractually structured so that 100% of any unused money goes to your listed beneficiaries on the policy when you die. The annuity company is on the hook to pay regardless of how long you live.

Contact Stan The Annuity Man for the best and highest QLAC quotes with all carriers using Stan's proprietary annuity calculators. You can also receive Stan's QLAC Owner's Manual for free and under no obligation, and see a live feed of the best fixed rates for your specific state of residence.

Link:
Qualified Longevity Annuity Contract Pros and Cons - TheStreet

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at http://www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

As with many websites, JD Supra's website (located at http://www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

We use cookies and other tracking technologies to:

There are different types of cookies and other technologies used our Website, notably:

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

Visit link:
Labor Department Issues Guidance on Calculating FLSA Regular Rate - JD Supra

The coronavirus pandemic has forced governments to face excruciating trade-offs. Benefit-cost analysis is a standard framework for making policy trade-offs, and some have suggested that it be used to make policy trade-offs in this pandemic. But benefit-cost analysis is flawed. We can do better.

The spread of this horrific virus has put front and center two types of trade-offs: Risk-income and risk-risk (risk here meaning fatality risk).

Shutting down businesses to enforce social distancing helps to flatten the curve, reducing individuals risks of dying from COVID-19. A flatter curve gives more time for the development of antivirals, the production of needed protective gear and medical devices and ultimately a vaccine. But a shutdown lowers individuals incomes. Income is reduced dramatically during the shutdown itself, and then later too if the shutdown causes a recession. How much should we as a society pay in lower incomes for a given flattening of the curve? This is a risk-income trade-off.

Looming shortages of gloves, masks and ventilators force us to think about rationing. Protective gear reduces fatality risk by lowering infection risk. Should police officers take priority over grocery store clerks in receiving N95 masks? This is a risk-risk trade-off. Medical devices cut down fatality risk among the infected. Which seriously ill patients should be put on ventilators if there arent enough ventilators for all? Should younger patients take priority over older ones? Again, a risk-risk trade-off.

Benefit-cost analysis is widely used by economists, and is now the dominant policy-analysis methodology in the federal government. It works as follows. Each positive or negative impact of a policy is converted into a monetary equivalent by asking how much individuals are willing to pay (for a positive impact) or willing to accept (in exchange for a negative one). The social value of a policy is calculated as the sum of the monetary equivalents for its positive impacts minus the sum of the monetary equivalents for its negative ones.

Valuing fatality risk reduction is nothing new for benefit-cost analysis. The linchpin is the so-called value per statistical life (VSL). An individuals willingness to pay for a risk reduction is just the risk reduction multiplied by VSL. Imagine that Felicias VSL is $6 million. This means that Felicia is willing to pay $6 for a 1-in-1 million risk reduction, $60 for a 1-in-100,000 risk reduction and $600 for a 1-in-10,000 risk reduction.

In principle, VSL varies among individuals. Felicias willingness to pay for risk reduction need not be the same as Victors. Textbook benefit-cost analysis says to convert individuals risk reductions into monetary equivalents using individual-specific VSLs. But this approach has dramatically counterintuitive implications when it comes to risk-risk trade-offs. Because richer individuals tend to have higher VSLs, textbook benefit-cost analysis gives them priority in risk reduction. It implies that richer patients should get priority in receiving ventilators.

The U.S. government in practice deviates from textbook benefit-cost analysis by using a single VSL for everyone (a population average). The number used is generally around $10 million. Benefit-cost analysis with a single VSL avoids giving priority to the rich in risk-risk trade-offs, but it has other difficulties.

First, it fails to give priority to the young in risk-risk tradeoffs. Do we really think that a rationing scheme for ventilators should not differentiate between 30 year-olds and 70 year-olds?

Second, benefit-cost analysis (whether we use individual-specific VSLs or a population average) is completely insensitive to the distribution of income. It surely matters how the costs of a shutdown are distributed across economic groups which in turn depends on the details of the fiscal policies that government puts in place to mitigate those costs. But benefit-cost analysis ignores income distribution; it says that society should be indifferent to whether the costs of a shutdown are borne by the poor, the middle class or the rich.

We can do better. A different methodology is sometimes used in economics, especially for tax policy and climate change. This methodology is called the social welfare function. Rather than translate policy impacts into monetary equivalents, this framework translates them into utilities. An individuals utility is a measure of her strength of preference for various goods (longevity, income, health and so forth). If Abigail prefers one bundle of goods to a second, the first bundle gets a higher utility.

Weve written about how the social-welfare-function approach can be applied to risk policies. In a nutshell, each cohort of similarly situated individuals (for example, age groups subdivided by income) can be seen as facing a lottery over longevity-income bundles. A given governmental policy shifts the lottery that each cohort faces. The simplest, utilitarian, version of this framework assigns a social value to a policy by summing expected utilities across cohorts. A different version, prioritarianism, gives extra weight to the worse off. As weve demonstrated, this methodology has important advantages over benefit-cost analysis when it comes to risk-income and risk-risk trade-offs. It gives preference to the young in risk-risk tradeoffs, but either mitigates (utilitarian) or eliminates (prioritarian) the preference for the rich. Moreover, it is sensitive to the distribution of costs preferring that income losses be borne by those higher up the socioeconomic ladder.

Benefit-cost analysis is a serviceable tool for grappling with trade-offs, but it can be improved on and the social-welfare-function framework shows how.

Matthew Adler is a professor of law at Duke Law School. James Hammitt is a professor of economics and decision sciences at the Harvard T.H. Chan School of Public Health.

Read the original:
A better way to grapple with benefit-cost trade-offs in a pandemic | TheHill - The Hill

USA TODAY Sports' Nate Davis breaks down the grades of some NFL teams after an eventful free agency period. USA TODAY

Bill Belichick still isn't in any mood to talk about Tom Brady.

Monday, the New England Patriots coach held a pre-draft conference call, the first time he'd spoken to reporters since Jan. 5 the day after the perennial AFC East champs' wild-card loss to the Tennessee Titans.

That playoff ouster also will represent the final time Brady, now a member of the Tampa Bay Buccaneers, suited up for the team that he led to nine Super Bowls and six Lombardi Trophies after New England drafted him in 2000.

"It would be of course impossible to sum up everything Tom did in 20 years into a comment, then or now," Belichick said Monday, according to The Boston Globe.

"Right now we're moving forward and focused on the draft here on this call."

For the first time since 2000, Tom Brady (12) and Patriots coach Bill Belichick won't be on the same sideline.(Photo: Greg M. Cooper, USA TODAY Sports)

Back in January, Belichick Mr. "We're on to Cincinnati," his mantra intended to keep the Patriots always looking ahead wanted to talk about the loss to the Titans, not Brady's future. Nowit's all about the draft, not reflecting on Brady's contributions over two stellar decades in Foxborough.

In between, on March 17, Belichick did say this of Brady, after he announced his intention to leave the Patriots: "Tom and I will always have a great relationship built on love, admiration, respect and appreciation.Toms success as a player and his character as a person are exceptional.Nothing about the end of Toms Patriots career changes how unfathomably spectacular it was.With his relentless competitiveness and longevity, he earned everyones adoration and will be celebrated forever.It has been a privilege to coach Tom Brady for 20 years.

NFL draft 2020 rankings: Chase Young, Joe Burrow headline top 50 rankings

Boom or bust: Jordan Love, Justin Herbert among 15 riskiest prospects in 2020 NFL draft

Who should pick a QB?: Recommendations for all 32 teams

"Sometimes in life, it takes some time to pass before truly appreciating something or someone but that has not been the case with Tom.He is a special person and the greatest quarterback of all-time."

Yet now, Belichick is unsurprisingly planning for life after Brady, second-year quarterback Jarrett Stidham currently the only quarterback listed on the team's roster. Veteran Brian Hoyer has agreed to return to the team in 2020, however his signing has yet to be officially announced.

Stidham threw only four passes in three brief appearances as a rookie but seems likely to get first crack at taking over for TB12.

The Patriots hold the 23rd pick of next week's NFL draft but don't pick again until No. 87, deep in the third round. Among this year's top passing prospects, Oregon'sJustin Herbert and Utah State'sJordan Love are the most realistic targets, but either might require a move up in Round 1.

Predictably, Belichick spoke in generalities about this year's incoming crop of passers, which also includesincludes LSU's Joe Burrow, Alabama'sTua Tagovailoa, Oklahoma'sJalen Hurts, Georgia'sJake Fromm and Washington'sJacob Eason.

Burrow is expected to be the first pick off the board to the Bengals, whileTagovailoa is widely projected as a top-five selection.

***

Follow USA TODAY Sports' Nate Davis on Twitter @ByNateDavis

Autoplay

Show Thumbnails

Show Captions

Read more here:
Bill Belichick on Tom Brady: Patriots 'moving forward and focused on the draft' - USA TODAY

The quality of a romantic comedy depends almost entirely on how much we root for the central couple. But sometimes, even in a good film, the couple falls short. Below, I have given scientifically calculated percentages for the likelihood that these couples stayed (happily!) together after the events of the film. Sony Pictures Releasing

Don't ask me how I got these numbers. Let's just say I crunched them. That sounds legitimate.

They definitely had a hot fling for a bit, but no WAY did they end up together. He was SUCH a dick to her and she didn't deserve that.

Cady and Aaron barely had one real conversation the whole movie. She only liked him because he was hot, and it was unclear why he liked her. Plus, he went off to college the next year! I doubt they stayed together past a few months of college.

Sandy totally changed herself for Danny!!! Even if they did last, Sandy would've grown to resent him for this. She probably sang an epic breakup ballad and dumped his ass.

Oh boy, I'm going to get a lot of hate for this one, but...Jake sucked. Their relationship sucked. There was way too much fighting and there was a REASON they were getting divorced. If it did last, it was a very unhappy marriage.

They might have stayed together, but I don't think they were happy. Their relationship started with an inherent power imbalance, and I don't think that would ever really change.

Like Mean Girls, this is another one where the characters really didn't know each other. AT ALL. Did they even have a conversation? I find it unlikely they stayed together, but since we really know nothing about them as a couple, it's hard to say.

They shared an emotional bond, but Austin was kind of a fuckboy and Sam deserved better. But they did go to the same college, so maybe they made it work there. I'm doubtful, though.

I don't know how they fell in love, because neither of them were themselves for pretty much the entirety of the movie. I feel like they just got caught up in the drama and passion, but who knows. Maybe they made it work once they revealed their true selves.

I'm actually a little unsure about both couples in this movie, but especially Amanda and Graham. They clearly had great chemistry and a good connection, but all the reasons they decided not to be together (before Amanda changed her mind) were really valid. I'm just not sure they would've been able to work out the logistics. I feel like the passion would start to fade.

This is such a fun movie, and I love Margaret and Andrew together, but I'm not sure they went the distance. I'm sure it put a strain on their relationship to get married before they really started dating, and I'm just not sure they were able to get over the power dynamic of their past. However, I do believe Andrew made Margaret better, and I rooted for them for sure!

I love Amy and Aaron together, and by the end of the film Amy had really stepped up and fought for that relationship. But I can't be sure she didn't fall back into old habits. I hope they ended up together forever, but it's hard to tell!

Look, this love story spanned DECADES! Even Will's daughter rooted for them!! He was so enamored with her and still thought of her so many years later. I truly believe their love could go the distance!! However, April was scared of commitment, so I can't say with certainty.

I don't believe in them quite as much as Allegra and Albert, because I feel like there were more lies here. But I also loved them together and I loved that Sara was really strong and independent and said what she felt. I think they were good for each other, and I'm hoping they made it work!!

First of all, Jamie and Dylan were really upfront with each other and had really great communication about sex, which we don't usually see in rom-coms. So we know that aspect of the relationship was good! PLUS, their relationship was built on an already strong friendship! I could see them as partners forever for sure.

I TOTALLY got why Scarlet wanted a divorce. But after turning into a teenager and discovering that even if he could go back, he'd make the same decisions, he learned to truly appreciate his wife again. I'm pretty sure they lived happily ever after!

Look, I know their whole relationship was sort of built on a lie since Albert hired Hitch to help him, but in the end it was revealed Allegra was just as dorky as him and loved all the things about him that Hitch told him to hide. They were SO CUTE together and I was so happy to see them get married at the end. I feel like they could entertain each other for decades.

Nick was willing to leave his family behind for Rachel, but Rachel wouldn't let him because she didn't want to tear apart his family. She truly fought for him, but in the end she wanted what was best. I was so glad they ended up together and I believe they stayed together for sure!

This movie tore my heart out!!! I was SO happy Jenna was able to go back and make things right with Matty so that they ended up together in the end. Jenna really truly loved Matty and just wanted him to be happy so much so that she was able to let him go!!! And Matty was amazing from the start. They were perfect for each other!!

Tell me that Hannah and Jacob were not MEANT FOR EACH OTHER!!!!! They are my fave rom-com couple EVER because they knew how to laugh together, and I truly believe they made each other better.

Apr. 10, 2020, at 19:02 PM

We referred to Albert from Hitch as Alfred a couple times. Oops!

Originally posted here:
I Have Some Strong Opinions On The Longevity Of These Rom-Com Couples So I Ranked Them - BuzzFeed

In two weeks, Larryand Mary Centolawill celebrate their marriage of 74 years, marking a joyous occasion amidst a worsening pandemic that has upended American life.

Its so sad. So many people have died, Mary, 94, said. I always count our blessings. I wake up in the morning, and I say: Thank you, God, for blessing us with another day of good health.

Like millions of otherLong Islanders, the New Hyde Park couple is hunkering down at home to slow the spread of the coronavirus. Neighbors are helping the Centolas, whose ages make them among the most susceptible to COVID-19, get groceries and necessities.

This year, the celebration will be small.

We will just toast to each other and wish each other another happy year, Mary said. I dont think I have any champagne left. So it will have to be wine.

As the nations annual divorce rate hovers between 40%and 50%, the Centolas nearly three-quarter-century marriage has left many wondering about the secret to their longevity, including North Hempstead Town Clerk Wayne Wink,who asked the coupleabout it during a Valentines Day celebration.

Mary, a devoutCatholic, attributed it to a lot of patience, love, understanding and faith.

Larry, 95, recounted the day they met in 1945, at a department store in Jamaica, Queens, where his future wife worked. He fought in World War IIand was on convalescent furlough when he accompanieda friend visiting his girlfriend at work.

Get the latest breaking news as it happens.

By clicking Sign up, you agree to our privacy policy.

I was very lucky to meet Mary by mistake, Larry told dozens of couples at the North Hempstead Town celebration. When I talked to herI said to myself: Shes a nice girl. So I said: Would you like to go for coffee? So from coffee, we were married.

The couple wed in a Queens church on April 28, 1946. Three years later, they moved into their home. Mary worked for the New York Telephone Company for 25 years, and Larry wasa jeweler in Manhattan for 45 years. They have no children.

They are not transient,said Denise Siciliano, Marys niece, whom the Centolas regard as their daughter.Im in my third house. They dont want to upset their applecart. Its their routine.

Siciliano, 70, of Westlake Village, California, went through a divorce in her 20s and said she believes her aunt and uncle are well-suited for each other.

When you know its right, its right, said Siciliano, who remarried and has been wed tohusbandArthurfor 45 years. Each of them are everything to each other. And its been like that since they got married.

The Centolas said they dont know thatthey have a secret to the longevity of their union. Larry said they enjoy each others company. Mary said she loves his carefree attitude and humor, and recalled a joke he told about hishospital stay after being bombed out of a foxhole in Germany.

He was knocked out unconscious for six days, Mary said.He woke up on Christmas Day and heard people singing. He thought he was in heaven.

Lasting love

See original here:
Larry & Mary + love and marriage = 74 - Newsday

As the facts surrounding the global coronavirus pandemic continue to change at a moments notice, its important to stay informed on the latest news. Doing so can help us make informed decisions to better protect our health. However, as important as it is to stay up to date with the latest news, could we also be harming our mental health?

Its understandable that we all want to spend our free time reading everything about the coronavirus as it helps to provide us with a sense of control, which is what we need during these uncertain times. However, its clear that absorbing too much bad news can be harmful to both our mental and physical health.

According to a survey from the American Psychological Association, most adults admitted to following the news regularly, but 56 % shared that doing so causes them stress. Now with that said, why do we still find ourselves glued to our screens, enamored with every sensational headline?

The fact is being informed allows us to develop tools that we can use to better protect ourselves. Unfortunately, being informed can often come as a cost to our mental health. For instance, research published in the British Journal of Psychology found that after just 14 minutes of watching bad news, participants began to experience negative effects on their mental health. Whats more, heightened stress levels can weaken your immune system, which is the last thing you need especially now.

However, this doesnt mean that you should give up on staying informed and engaged. In fact, there are ways for you to stay informed without compromising your mental health.

Similar to how you establish screen time limits for your kids, you should also set your own time limits when it comes to reading the news. Clicking on a link with a sensational headline can catapult you down a rabbit hole of never-ending information. However, by setting an alarm, you can pull yourself out before you get in too deep and compromise your mental health.

Try to figure out how much time youll need to read the news, and set an actual timer on your phone, be it for 5, 15, or 30 minutes or even an hour. You should then decide how many times a day youll do it for say reading the news for 15 minutes three times per day. Once the time is up, close all your apps or tabs related to the news, and dont open it up again until the next time, or day.

In addition to timing yourself when it comes to reading the news, you should also remember to allocate time to other activities that are good for your mental health. This includes exercising, reading, or any other healthy hobbies.

Different news sources help to provide you with more perspective when it comes to current affairs. However, the constant and multiple news alerts and notifications on your phone can get overwhelming, raising your stress levels.

As such, it would be advisable to limit your notifications and only allow news alerts from sites that you deem necessary. In fact, more information is not necessarily the best way to stay informed. Instead of allowing a barrage of notifications to fill up your phone, rather choose just two or three of the most credible sources and ignore the rest. Sites such as the CDC and the WHO organization are the best sources as they provide the latest, and the most credible information surrounding the coronavirus.

When a news story breaks, were all glued to CNN or refreshing our Twitter timelines in an effort to get the latest updates. While normal, this action can affect your mental health. This is because when a news story breaks, it takes a while to get all the facts straight and oftener than not, the information we see online is more so based on half-truths, speculations, and even conspiracy theories. As a result, these stories may serve to get our attention, but they also serve to increase anxiety and stress levels.

As it takes some time for journalists to collect all the facts, it would be advisable to wait for them to provide a more accurate and well-rounded report.

The last thing you want is to be going to bed with news anxiety, as this will disrupt your sleep, and this is the last thing you need. In addition to weakening your immune system, lack of quality sleep can also affect your mental health by increasing the risk of depression.

Its important to never check the news before bed. This is because you want enough time during the day to process the information. During the day, if you read something that raises your stress levels, youll be able to engage in stress-relieving techniques such as yoga or meditation. Its also advisable to not sleep with your phone too close to you as you may be tempted to read the news as soon as you wake up.

With the constant influx of infection rates and death tolls, the news can get quite depressing. However, its important to remember that there are good things happening in the world. The bad news does not provide a full picture of the days events.

Reading good news can help to relieve some stress accumulated by bad news. So, try to read up on some human interest stories or you can also follow sites like the Good News Network, Positive News, and Optimist Daily.

In addition to getting some good news, you should also try focusing on issues that you can help solve. As the coronavirus pandemic has affected various people in different ways, why dont you go out of your way to research how you can help them? For ways to get involved, or help make a change, check out Global Givings Coronavirus Relief Fund.

Starting your day reading bad news can affect your mood. So, its important to start your day on a more positive note.

Try starting your day by listening to a relaxing podcast that boosts your mood, exercising, meditating, or by even enjoying a cup of coffee on your porch, enjoying the tranquil silence.

If youve been consuming the news, and youre feeling overwhelmed, its important not to suppress your feelings. Doing so can make things worse.

Instead, try reaching out to a friend or family member and talk about your feelings. Additionally, your area may be on lockdown, but psychologists and counselors are still operating online. Therefore, dont shy away from contacting your nearest mental health counseling group.

Yes, you should reach out if you are feeling overwhelmed with crippling coronavirus anxiety. However, you can also make the conscious decision not to discuss the coronavirus if you believe that doing so affects your mental health.

When it comes to the coronavirus, everyone has an opinion, and theyre each looking to share it. As a result, we often feel forced into a conversation. However, youre allowed to not engage if you feel that doing so can bring your mood down. Feel free to change the subject to something more positive.

If all else fails, feel free to simply step back and unplug.

Youre allowed to protect your mental health. If you feel that you need to disconnect from time to time, feel free to do so. Uninstall all your social media apps and disconnect from all news outlets for a period of time. Ask a close friend or family member to only alert you if something is going on that you need to know about.

Yes, its important to stay up to date with the news as this can help us to make more informed decisions. Unfortunately, too much news can affect our health, and thats the last thing we need right now.

Thankfully, there are ways to protect our health and stay informed.

Johnston, W.M. and Davey, G.C.L. (1997), The psychological impact of negative TV news bulletins: The catastrophizing of personal worries. British Journal of Psychology, 88: 85-91. DOI:10.1111/j.2044-8295.1997.tb02622.x

See the rest here:
Here Are 9 Ways To Stay Informed and Protect Your Mental Health - Longevity LIVE

Andrea Bocelli, 61, is the Italian opera singer who will give a special performance at the Duomo of Milan on Easter Sunday,sending a message of love to the world during the coronavirus pandemic. The Italian tenor said of his upcoming performance that it will not be a concert but instead a prayer for the world during one of the most difficult times in our lives. The singer will be accompanied by organist Emanuele Vianelli and will be singing at the historic cathedral. Many believe Bocelli was born blind but in fact he had lost his sight at 12 years old after a football accident.

To say Bocelli has a good voice is an understatement.

Celine Dion described his voice and said: If God would have a singing voice, he must sound a lot like Andrea Bocelli.

Bocelli has soldmore than90 million records worldwide and has brought classical music back into the mainstream.

Bocelli was born with poor eyesight, however, became fully blind after a football accident.

The singer was hit in the eye playing goalkeeper during a match and suffered a brain haemorrhage.

Doctors tried in vain to help restore Bocellis sight, even resorting to using leeches in a last-ditch effort, buttheywere sadly unsuccessful and he remained blind.

Despite his traumatic accident, Bocelli has gone on to become one of the worlds best-selling artists of all time and never allowed his loss of sight to be a hindrance in his career.

The NHS said: A subarachnoid haemorrhage is most often caused by a burst blood vessel in the brain.

A brain aneurysm is a bulge in a blood vessel caused by weakness in the blood vessel wall, usually at a point where the vessel branches off.

As blood passes through the weakened vessel, the pressure causes a small area to bulge outwards like a balloon.

Occasionally, this bulge can burst, causing bleeding around the brain.

Around eight out of every 10 subarachnoid haemorrhages happen in this way.

A brain aneurysm doesnt usually cause any symptoms unless it ruptures.

But some people with unruptured aneurysms experience symptoms such as sight problems, pain on one side of the face or around the eye and persistent headaches.

The BMJ said: Blindness may occur simultaneously with the haemorrhage, it occurs just as frequently after an interval of several days and even weeks.

It would seem to be important to separate these two varieties of blindness in view of their different prognosis, and also in view of the fact that the former recovers with no therapy, whereas the latter variety has a uniformly bad prognosis in spite of treatment.

These cases are not, however, clearly separated in the literature.

It would seem that the former variety is associated with a rapid reduction in the blood-volume and afall in blood-pressure.

Read the original post:
Andrea Bocelli health: How did the singer become blind - symptoms - Express.co.uk

This article is inThe Spectators April 2020 US edition.Subscribe here to get yours.

Before the COVID-19 scare I never thought that one particular Spanish proverb would come in useful. It goes: Los ojos con los codos. This hardly seems to make sense, Eyes with the elbows, but the great 19th-century traveler Richard Ford explains in his Gatherings from Spain that the suns glare on the dusty land may inflame the eyes, which must never be rubbed with the hand, only with the elbow, lest ophthalmia and blindness set in. He also recommends blue gauze spectacles, which I must out.

Now, with the coming of the coronavirus, the public-spirited sneezer will use a pad of paper tissues in her hand, or sneeze into the crook of her elbow, rather than into her hand, which might then infect door handles, transportation-carriage poles or escalator handrails.

It is impossible to use the point of the elbow on the eyes; you cant reach. I mentioned the crook of the elbow, but the Oxford English Dictionary seems to limit the reference of elbow to the pointed, angular part. The elbow is literally the bend (bow) of the ell (which gives us the obsolete measurement), though the Old English word had an n in it: eln. That word is related to Latin ulna (which we use technically for the bone beside the radius). What the inside angle of the elbow is called, who can say? My husband was useless when I asked him, going on about the antecubital fossa. Some call it the elbow-pit, but the OED is ignorant of this term.

Someone who hasnt a clue is often said not to know his ass from his elbow. Richard Ford doesnt give the acknowledged Spanish equivalent, but it is confundir el culo con las tmporas cant tell his ass from his ember days. Ember days are more recondite than elbows, being quarterly fast days, to wit: the Wednesday, Friday, and Saturday following the first Sunday in Lent, Whitsunday, Holy Cross Day (September 14) and St Lucys day (December 13). The origin of ember is most straightforwardly found in the Old English ymbren, meaning revolution of time. But scholars tell us that ember might after all be a corruption of Latin tempora.

Digging up reliable etymologies takes a lot of elbow grease.

This article is inThe Spectators April 2020 US edition.Subscribe here to get yours.

Continue reading here:
What do elbows have to do with fighting coronavirus? - The Spectator USA

Regeneron's (NASDAQ:REGN) stock has increased by 34% in 2020 as the company and its partner Sanofi (NASDAQ:SNY) initiated two large scale phase 2/3 clinical trials in March where it is providing an existing drug, Kevzara, to treat patients with severe COVID-19, the disease caused by the novel coronavirus. This development has investors optimistic about its prospects. But Regeneron's financial performance for the full year will be driven by the company's core business of treating eye diseases, asthma, eczema, and cancer.

Let's take a closer look at the biotech stock's main revenue drivers to decide if it's a buy today.

IMAGE SOURCE: GETTY IMAGES

As of April 9, there have been over 1.4 million worldwide confirmed COVID-19 cases and almost 90,000 virus-related deaths. While there are no approved drugs to effectively treat COVID-19 patients, many companies, including Regeneron, have commenced clinical trials to determine whether existing compounds used for other diseases can help these patients recover.

In March, Regeneron and Sanofi announced that they initiated two large phase 2/3 trials to assess whether Kevzara can prevent lung damage and respiratory distress in patients with severe COVID-19. Regeneron and Sanofi currently market Kevzara as a treatment for adult patients with rheumatoid arthritis (RA). Kevzara blocks the interleukin-6 (IL-6) protein, which may cause a patient's immune system to overreact and damage the lungs.

Recently, a preliminary study performed at a Munich Hospital found patients who have a minimal amount of IL-6 protein have significantly lower rates of respiratory failure and may not need mechanical ventilation. Earlier, a small Chinese study showed that patients who received Actemra, Roche Holdings' (OTC:RHHBY) IL-6 receptor antagonist and competing RA drug, were able to be discharged from the hospital and return home.

Eylea, an injectable drug that prevents blindness, grew by 14% in the U.S. to over $4.6 billion in 2019 (about 60% of Regeneron's sales). Eylea's revenues should continue to increase as it the company fully launches a pre-filled syringe delivery option for physicians and continues to market to the drug to adults with age-related macular degeneration (AMD), a disease that affects almost 11 million people in the U.S and is the leading cause of vision loss in Americans 60 and older. Eylea prevents the disease from progressing to an advanced stage and results in rapid, large sustained improvement for patients with mild to moderate AMD.

Regeneron will also benefit from growth in its diabetic eye business as it has established a dedicated salesforce to specifically contact specialists that see these types of patients. The company is devoting a significant amount of resources to improve on the low current rates of diagnosis and treatment of diabetic retinopathy (DR). DR is a complication of diabetes that causes damage to the retina and can lead to severe vision loss. Early treatment with Eylea, however, can halt the progress of DR, reducing the risk of blindness. This is a welcome development for the almost 8 million people who have DR.

Dupixent sales reported by Sanofi grew by almost 151% to over $2.3 billion in 2019 as physicians prescribed the drug to other adult patients with eczema and treated patients in three new sub-segments (asthma, children with eczema, and adults with chronic long-term sinus inflammation linked to nasal polyps). While Sanofi records all of global Dupixent sales on its income statement, it paid Regeneron over $1.4 billion in contribution revenue in 2019, up 40%, relating to royalties and profits from Dupixent (and two other drugs).

Dupixent should continue to grow as it is used for other patients in these three markets and it will enjoy further growth if it obtains approval from the Food and Drug Administration (FDA) for using the drug for asthma in pediatrics, chronic obstructive pulmonary disease, eczema in pediatrics, and several other indications.

Regeneron generated $176 million in revenue from Libatyo in 2019, up from almost $15 million in 2018. Libtayo treats advanced Cutaneous Squamous Cell Carcinoma (CSCC), a form of skin cancer that accounts for an estimated 7,000 deaths each year in the U.S. As of November 2019, its share of U.S. patients with CSCC was 43%, up from 3% when it was launched in October 2018.

Regeneron is currently testing Libtayo in Non-Small Cell Lung Cancer (NSCLC) patients, cervical cancer, and Basal Cell Carcinoma (BCC; the most common form of skin cancer). Libtayo's revenues should increase in the near-term as physicians continue to prescribe the drug for their CSCC patients and the drug is eventually used in other types of cancers.

I consider to be Regeneron a buy right now because it has ample opportunity to increase the revenue and profits it currently generates from its three key drugs, Eylea, Dupixent, and Libtayo. While investors will be waiting for further updates on Kevzara, they should focus and monitor Regeneron's progress in expanding its the diabetic eye segment, further penetrating the three emerging areas for Dupixent, gaining market share in CSCC, and obtaining FDA approval for treating other indications with these drugs.

While it's easy to be enthralled by its progress in the COVID-19 space, investors thinking about buying Regeneron would do well to consider the stock from a more holistic stance. And it looks good from here.

Originally posted here:
Here's Why Regeneron's Stock Is Worth More Than Its Coronavirus Work - Citybizlist Real Estate

A BRAVE boy who won the nation's heart in his battle against leukaemia gave his millions of fans a thumbs up after being discharged from hospital and declared cancer free.

Oscar Saxelby-Lee, 6, was diagnosed with an aggressive blood cancer in December 2018 after his parents noticed unusual bruising on his legs.

Doctors gave Oscar, from Worcester, just months to find a stem cell match to save his life which led parents Olivia Saxelby, 25, and Jamie Lee, 28, to launch a UK-wide appeal for donors.

Last March, a record-breaking 4,855 volunteers queued in the freezing rain after Oscar's Pitmaston Primary School in Worcester opened as a testing centre.

A suitable donor was finally found after a staggering 10,000 people were tested across the UK.

Just months later, Oscar's family faced further anguish when his rare T-cell acute lymphoblastic leukaemia returned.

But after a crowdfunding campaign raised 600,000, his family flew him to Singapore to undergo CAR-T therapy - a pioneering treatment not available on the NHS.

Oscar became only the second child in the world to have the treatment before having a second bone marrow transplant.

Now the boy's thrilled mum Olivia has confirmed he is out of hospital and cancer free.

In a touching picture, brave Oscar, nicknamed Ozzy Bear by his parents, posed in his car seat wearing a protective mask and giving a massive thumbs up.

Writing on the 'Hand in Hand for Oscar' Facebook page, followed by millions worldwide, she said: "He's only gone and done it!!!!!!!

"Thank you from the bottom of our hearts to our AMAZING team at National University Hospital - NUH, you have made miracles happen!

Delighted Olivia added: "We love you all!

"HOME SWEET HOME, WHEREVER IT WILL BE!"

Jen Kelly, director of the Grace Kelly Childhood Cancer Trust, who has kept in touch with the family, said:"They have now been in Singapore for six months and it is incredible that he is still cancer free and that his bone marrow transplant has gone well to date.

"We would like to say a big thank you to the people of Worcestershire for helping us give this lifesaving chance to Oscar and his family."

While Oscar is now out of hospital, he is still returning frequently to Singapore for treatment so will remain there for several more months before returning home to Worcester.

Live Blog

VIRUS CRISISUK death toll hits 10,612 AS HALF of A&E team test positive for Covid-19

BOJO'S ANGELSHero nurses who saved Boris' life pictured after he's released from hospital

STAY AT HOME!Brits flout corona lockdown to soak up 22C heat - as even cemeteries close

CORONA HOPEBritish corona vaccine could be just WEEKS away with experts '80% confident'

TRUCKING HELLFood & medicine supply crisis looms after half UK's lorries taken off road

Throughout his treatment, Oscar has kept in touch with his classmates and teachers from his hospital bed via an innovative robot - nicknamed "Ozzybot".

His headteacher Kate Wilcock, who organised the huge donor registration event and Ozzybot lessons, said: "Incredible news his last results are MRD negative, no disease.

"We are absolutely blown away - the dream has become a reality.

2

2

We pay for your stories! Do you have a story for The Sun Online news team? Email us at tips@the-sun.co.uk or call 0207 782 4368 . You can WhatsApp us on 07810 791 502. We pay for videos too. Click here to upload yours.

Go here to see the original:
Brave boy, 6, who won the nations heart as he battled leukaemia gives a thumbs up after being discharged f - The Sun

The Autologous Stem Cell and Non-Stem Cell Based Therapies market research encompasses an exhaustive analysis of the market outlook, framework, and socio-economic impacts. The report covers the accurate investigation of the market size, share, product footprint, revenue, and progress rate. Driven by primary and secondary researches, the Autologous Stem Cell and Non-Stem Cell Based Therapies market study offers reliable and authentic projections regarding the technical jargon.

All the players running in the global Autologous Stem Cell and Non-Stem Cell Based Therapies market are elaborated thoroughly in the Autologous Stem Cell and Non-Stem Cell Based Therapies market report on the basis of proprietary technologies, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines R&D developments, legal policies, and strategies defining the competitiveness of the Autologous Stem Cell and Non-Stem Cell Based Therapies market players.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2439434&source=atm

The major players profiled in this report include:U.S. STEM CELL, INC.Brainstorm Cell TherapeuticsCytoriDendreon CorporationFibrocellLion BiotechnologiesCaladrius BiosciencesOpexa TherapeuticsOrgenesisRegenexxGenzymeAntriaRegeneusMesoblastPluristem Therapeutics IncTigenixMed cell EuropeHolostemMiltenyi Biotec

The end users/applications and product categories analysis:On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-Embryonic Stem CellResident Cardiac Stem CellsAdult Bone MarrowDerived Stem CellsUmbilical Cord Blood Stem Cells

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Autologous Stem Cell and Non-Stem Cell Based Therapies for each application, including-Neurodegenerative DisordersAutoimmune Diseases Cancer and TumorsCardiovascular Diseases

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2439434&source=atm

Objectives of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Study:

The Autologous Stem Cell and Non-Stem Cell Based Therapies market research focuses on the market structure and various factors (positive and negative) affecting the growth of the market. The study encloses a precise evaluation of the Autologous Stem Cell and Non-Stem Cell Based Therapies market, including growth rate, current scenario, and volume inflation prospects, on the basis of DROT and Porters Five Forces analyses. In addition, the Autologous Stem Cell and Non-Stem Cell Based Therapies market study provides reliable and authentic projections regarding the technical jargon.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2439434&licType=S&source=atm

After reading the Autologous Stem Cell and Non-Stem Cell Based Therapies market report, readers can:

Here is the original post:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Incredible Possibilities, Growth With Industry Study, Detailed Analysis And Forecast To...

SINGAPORE: It was a moment of pure elation for the family of Oscar Saxelby-Lee the six-year-old has finally been discharged from hospital after staying cancer-free for nearly three months.

The British boy has been battling acute lymphoblastic leukaemia since December 2018, and arrived in Singapore forexperimental treatment at the National University Hospital (NUH) that only one other child in the world has received.

Doctors in the UK said that they had exhausted all conventional treatment and that there was only palliative care left for Oscar. Thefamily was told to prepare for the worst.

But after arriving in Singapore in November and starting treatment on Christmas Eve, Oscar has remained MRD (minimal residue disease) negative which means no cancer cells are detected for nearly three months.

He was discharged from hospital on Thursday (Apr 9) and will go back for check-ups every few days.

His mum Olivia told CNA it is the longest period her only son has remained cancer-free since he was diagnosed.

Oscar is defeating the odds. After being told end-of-life care was the only option left for Oscar about eight months ago, he has shown that miracles really do happen, she said.

He is the best he has been in a very long time full of life, living life and enjoying life again.

It has been a huge learning curve, and no doubt will continue to be, but we are grateful. Grateful for this chance, grateful for the team saving Oscars life and also grateful for the experience.

It still feels a little like a dream. We just cant believe it. NUH has saved Oscars life!

NUH TREATMENT WAS OSCARS LAST HOPE

The treatment in Singapore was Oscars last hope. All other treatments had failed to rid him of the cancer - he was still MRD positive after a stem cell transplant and rounds of chemotherapy.

The little boy from Worcester, England flew to Singapore after the family crowdfunded 500,000 (S$885,000) for a new form of treatment, in which immune cells from a patients blood is drawn and equipped with a Chimeric Antigen Receptor (CAR-T).

The receptor binds itself to a specific protein on the cancer cell and activates the CAR-T cells to kill the cancer cells.

This particular form of CAR-T treatment is different and more difficult because the leukaemia cells resemble Oscars immunity system, Associate Professor Allen Yeoh, head of paediatric oncology at NUH, explained previously.

This is compassionate treatment,which means it is not even in the medical trial stage yet.

By the time he arrived in Singapore, Oscar wasweak from the months in hospital isolation and from battling the rare blood cancer.

He got stronger and doctors started treatment on Christmas Eve. On Jan 15, his parents were told he was MRD negative but that was just the first major step towards a full recovery.

Over the last three months, Oscar has battled several conditions as a result of complications and undergone more surgeries and transplants.

He was diagnosed with both Graft versus host disease (GvHD) and Thrombotic microangiopathy(TMA) that caused him shaking spells, pain and weakness.

"WE NEEDED MUM HERE"

Over the last five months, Oscars family has remained in Singapore far from their loved ones in the UK.

Shortly before the COVID-19 pandemic broke out, Oscars grandmother Oomar travelled to Singapore to be with her grandson.

We needed her with us after such a long haul of trauma. She flew knowing of the risks (of contracting COVID-19) and was very worried, Olivia said.

Oomar completed her 14-day stay-home notice and was allowed to see Oscar just as he was overcoming the worst of the TMA.

This was the moment Oscar saw his grandmother for the first time in months:

Oscars life instantly became better, he was ecstatic, said Olivia.

She has been a huge lift for us all, for me especially as well. We all need our mums at times. An extra pair of hands, loving support and someone else to talk to.

The family will remain in Singapore and keep Oscar isolated at the apartmentwhere they've been staying as his immunity system is still recovering, and he will make frequent trips to outpatient clinics in hospital, his mum said.

He isnt out of the woods yet. Being post-transplant puts him even more at risk, and very vulnerable to not just COVID-19, but any cold or illness, she explained.

Thats nearly a year and a half of complete isolation and even in the future, we will have to be very vigilant.

"SINGAPORE IS AN AMAZING COUNTRY"

With the COVID-19 outbreak affecting countries around the world, including the UK and Singapore, the family will stay in Singapore until Oscar has been given the all-clear to fly home.

We all miss home. We miss our friends, our family, our society, our community, Olivia said.

We are really homesick, but we are safe, and we believe we are in the safest place. Singapore is an amazing country, and we feel privileged to be here, even at this difficult time.

We have met so many wonderful people here, from friends, to medics ... each has been an incredible support for us as a family.

Our lives have changed greatly.

The support has been so heartwarming. The well wishes and prayers truly mean so much to us. We are touched by peoples generosity, care and compassion for us as a family and cannot thank everyone both here and back home enough.

Its been one heck of a journey, and Im sure will continue to be, but the support makes it all that little easier.

Read more:
British boy fighting rare cancer is discharged after coming to Singapore for experimental treatment - CNA

ISLAMABAD, (UrduPoint / Pakistan Point News - 12th Apr, 2020 ) :Chairman Task Force of Pakistan Science and Technology, Dr Ata ur Rehman on Sunday said that combination of two drugs would have better results in treating coronavirus patients.

The clinical trials of patients had been carried out in Karachi and Lahore for checking the results of Anti-malarial and Erythromycin drugs, he stated in a ptv programe.

The Americans had tested "Hydroxychloroquine in treatment of patients infected with coronavirus but the result was appearing negative. We hope that in Pakistan, Hydroxychloroquine" plus "Erthromycine" would produce results after treating patients of this spreading virus, he added.

The university of health sciences (UHS), was undergoing testing with some 1100 patients to check the effectiveness of the combination of two drugs, he said. "These are different approaches, where our scientists, experts and pathologists were working, " he said. The Chairman hoped that combination of two drugs would be helpful for patients of coronavirus. To a question about threshold of virus, he said intensity of COVID-19, here was less pernicious as compared to European regions.

The Chairman Task Force said the research was underway in different labs of Pakistan for identifying the stages of mutation. Expressing his view as an eminent scientist, he said some nine mutation were being observed in the virus that had entered into this part of the region from outside.

He said intensity of the virus was not as much higher as in the European countries. To another question, he said that Dr Tahir Shamsi, and his team was working on a project of plasma for treating coronavirus patients.

While Dr S.Shah Nawaz with her team was working on stem cell. The third approach, he said that a pharmaceutical company had acquired a shrub from China and for approval, the summery has been sent to Drugs Regulatory Authority of Pakistan (DRAP). About the families of virus, Dr Ata ur Rehman said that we simply called it a third family virus appeared before the world namely COVID-19. He said in the recent history, there was a middle Eastern Respiratory Syndrome (MERS), and Severe Acute Respiratory Syndrome (SARS).

See original here:
Combination of two drugs better results in treating coronavirus patients: Dr Ata - UrduPoint News

VANCOUVER, Washington, April 06, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn or the Company), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the first two COVID-19 patients have been treated with leronlimab under the Companys Phase 2 randomized clinical trial, which is for patients with mild-to-moderate indications. The Company anticipates that enrollment of more patients will accelerate this week at multiple clinical sites.

In addition, the Companys investigational new drug, leronlimab, has now been administered to 15 severely ill COVID-19 patients at four hospitals, 10 patients treated at a leading medical center in the New York City area and five patients at three other hospitals, all under an emergency investigational new drug (EIND), which were granted by the U.S. Food and Drug Administration (FDA) for each individual patient.

CytoDyn also anticipates initiating its other COVID-19 trial this week. This trial is a Phase 2b/3 for severely ill COVID-19 patients and is for 342 patients, double-blinded with a 2:1 ratio (drug to placebo ratio). Patients enrolled in this trial are expected to be administered leronlimab for two weeks, with the primary endpoint being the mortality rate at 14 days. The Company will perform an interim analysis on the data from 50 patients following two weeks of leronlimab therapy.

Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostic partner and advisor to CytoDyn, commented, We are encouraged by the positive results demonstrated with leronlimab in the New York patients. Our team is working hard to distribute leronlimab to multiple clinical sites to initiate therapy in patients with severe COVID-19 disease. While every patient is experiencing different comorbidities, we are seeing similar clinical responses, which we believe is a reflection of leronlimabs mechanism of action.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, said, Our partnership with the New York medical team and now other hospitals has been exemplary. We are collaborating in every aspect to deliver leronlimab to patients in order to provide proof of concept as soon as possible. The outstanding coordination among the physicians, the hospital administrators, the FDA, and our team, will hopefully help mitigate the deleterious effects from this pandemic should we prove leronlimab as a solution. The lead physician in New York is a true medical hero, who deserves to be recognized for his contribution to humanity in the pandemic of COVID-19. We are very hopeful of sending the day three and day seven results of the first ten EIND patients to the FDA by the end of this week.

About Coronavirus Disease 2019SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.

About Leronlimab (PRO 140) The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD.

About CytoDyn CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in April of 2020 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at http://www.cytodyn.com.

Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes, hopes, intends, estimates, expects, projects, plans, anticipates and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Companys forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Companys cash position, (ii) the Companys ability to raise additional capital to fund its operations, (iii) the Companys ability to meet its debt obligations, if any, (iv) the Companys ability to enter into partnership or licensing arrangements with third parties, (v) the Companys ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Companys ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Companys clinical trials, (viii) the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTSInvestors: Dave Gentry, CEO RedChip Companies Office: 1.800.RED.CHIP (733.2447) Cell: 407.491.4498 dave@redchip.com

More:
First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency...

Type 2 diabetes affects insulin in the body. Symptoms of type 2 diabetes include increased thirst, increased hunger, headaches and tiredness. Everybody needs insulin to live and has an essential job to help keep the body healthy. Insulin allows the glucose in the blood to enter the cells and fuel the body. When a person has type 2 diabetes, the body still breaks down carbohydrate from the food and drink and turns it into glucose.

The pancreas responds to this by releasing insulin, however, this insulin cant work properly, and blood sugar levels keep rising and more insulin is released.

This plays havoc on the body with various warning signs that the blood sugar levels are too high.

Left untreated, high blood sugar levels could cause strokes or heart attacks.

There is another side effect to ones health caused by high blood sugars and is knowns as neuropathy.

What is it?

For people with type 2 diabetes, foot complications such as neuropathy and circulation problems can make it difficult for wounds to heal.

Serious problems could arise and other foot issues such as calluses are also common in people with type 2 diabetes.

While calluses may not seem a big problem, left untrimmed they can turn into ulcers or open sores.

People with diabetes are also at risk for Charcot joint, a condition in which a weight-bearing joint progressively degenerates, and this could lead to bone loss or deformity in the feet.

The NHS said: Peripheral neuropathy develops when nerves in the bodys extremities, such as the feet, are damaged.

The symptoms depend on which nerves are affected. In the UK its estimated almost one in 10 people aged 55 or over are affected by peripheral neuropathy.

The main symptoms of neuropathy can include a numbness and tingling in the feet or hands, burning, stabbing or shooting pain in affected areas, loss of balance and co-ordination and muscle weakness, especially in the feet.

These symptoms are usually constant but may come and go.

Read the original here:
Type 2 diabetes: The major warning in your feet due to blood sugar levels being too high - Express